How to Inject Tirzepatide

Tirzepatide is available in two primary forms:

• Single-dose auto-injector pens (Mounjaro®, Zepbound®) — Pre-filled, pre-measured pens manufactured by Eli Lilly. Each pen contains one dose and is discarded after use. No reconstitution or dose selection is needed.
• Compounded tirzepatide vials — Multi-use vials containing lyophilized powder that must be reconstituted with bacteriostatic water. Doses are drawn with an insulin syringe. Available through compounding pharmacies.

The auto-injector pen is the simplest option — you unlock it, place it on your skin, and press the button. Compounded vials require more steps but offer more flexible dosing.

The Mounjaro/Zepbound auto-injector requires minimal handling:

1. Remove from refrigerator 30 minutes before injection to reach room temperature. Do not remove the gray base cap until you're ready to inject.
2. Check the solution. Look through the inspection window — the solution should be clear, colorless to slightly yellow. Do not use if cloudy, discolored, or containing particles.
3. Choose your injection site. Clean the area with an alcohol swab. Approved sites: abdomen (2+ inches from navel), front of thigh, or upper arm.
4. Remove the gray base cap by pulling it straight off. You'll see the needle guard — the needle is hidden inside.
5. Place the pen flat against your skin at the injection site. Do not pinch the skin when using the auto-injector.
6. Unlock and press. Turn the lock ring to unlock. Press and hold the purple injection button. You'll hear two clicks — the first starts the injection, the second indicates it's complete.
7. Hold for 10 seconds after the second click to ensure full dose delivery. A gray plunger will be visible in the inspection window when complete.
8. Remove and dispose in a sharps container. Do not reuse or recap.

For compounded tirzepatide vials (lyophilized powder):

1. Reconstitute. Add bacteriostatic water per the label instructions. For a 10 mg vial, adding 2 mL yields 5 mg/mL. Aim the water stream against the glass wall and swirl gently.
2. Calculate dose volume. At 5 mg/mL: a 2.5 mg dose = 0.5 mL (50 units), a 5 mg dose = 1.0 mL (100 units).
3. Draw your dose with a clean insulin syringe. Remove air bubbles.
4. Clean the injection site and pinch a fold of skin.
5. Inject at 90° into the subcutaneous fat layer. Depress the plunger slowly over 5–10 seconds.
6. Withdraw, apply pressure, and dispose of the syringe properly.

Dose reference (10 mg vial + 2 mL BAC water = 5 mg/mL):

For doses above 5 mg at 5 mg/mL concentration, you may need two separate draws with a 1 mL syringe, or reconstitute with less water for a higher concentration.

Tirzepatide is injected subcutaneously in the same sites as other GLP-1 receptor agonists:

• Abdomen — At least 2 inches from the navel. The most common and accessible site.
• Front of the thigh — The middle outer area between the knee and hip.
• Back of the upper arm — Assistance may be needed.

Rotate injection sites weekly. Do not inject into areas that are tender, bruised, red, hard, or scarred. If using tirzepatide alongside other injectable medications, do not inject them at the same site.

Tirzepatide follows a gradual dose escalation to reduce gastrointestinal side effects:

Side effect management tips:

• Follow the titration schedule — do not increase dose faster than every 4 weeks
• Eat slowly and stop eating when full — tirzepatide significantly reduces appetite
• Avoid fried, fatty, and high-sugar foods, which worsen nausea
• Stay well hydrated with water and electrolytes
• If GI side effects are severe, stay at your current dose for an additional 4 weeks before escalating

Tirzepatide is an FDA-approved prescription medication (Mounjaro® for type 2 diabetes, Zepbound® for chronic weight management). It should only be used under medical supervision.

Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in animal studies. It is contraindicated in individuals with a history of medullary thyroid carcinoma or MEN 2 syndrome. Report severe abdominal pain, vision changes, or signs of hypoglycemia to your healthcare provider immediately. This article is for educational purposes only and does not constitute medical advice.